Ultrasound mediated nonviral gene therapy - SonoThera
Latest Information Update: 13 Oct 2025
At a glance
- Originator SonoThera
- Class Gene therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Duchenne muscular dystrophy
Most Recent Events
- 08 Oct 2025 Pharmacodynamics data from a preclinical data from Duchenne muscular dystrophy released by SonoThera
- 07 Dec 2024 Ultrasound mediated nonviral gene therapy - SonoThera is available for licensing as of 07 Dec 2024. https://sonothera.com/contact/
- 07 Dec 2024 Preclinical trials in Duchenne muscular dystrophy in USA (IV), before December 2024